Printer Friendly

FDA ADVISORY COMMITTEE MAKES RECOMMENDATION FOR APPROVAL OF BRISTOL-MYERS SQUIBB COMPANY'S ANTIDEPRESSANT DRUG

 WASHINGTON, July 19 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration's Psychopharmacological Drugs Advisory Committee recommended approval for Nefazodone Hydrochloride Tablets for the treatment of major depression.
 The company also announced that the trade name for its new antidepressant drug will be SERZONE(TM) (nefazodone hydrochloride) Tablets.
 Clinical depression is a serious medical illness that affects more than 11 million Americans each year. Medical research has found that people who suffer from depression have abnormally low functional levels of certain neurotransmitters in the brain, such as serotonin.
 SERZONE increases serotonin by two complementary actions. SERZONE potently blocks the post-synaptic 5HT(subscript 2) receptor and also inhibits pre-synaptic re-uptake of serotonin.
 "The company is very pleased with the decision made today by the Food and Drug Administration's Pyschopharmacological Drugs Advisory Committee as well as the cooperation we've had since submitting the NDA (New Drug Application) in September 1991," said Kenneth M. Given, M.D., senior vice president regulatory affairs.
 Following the Advisory Committee's action, the FDA must make a final determination as to whether SERZONE meets all applicable safety and efficacy requirements before the final product approval.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological therapies, diagnostic agents and non- prescription medicines.
 /delval/
 -0- 7/19/93
 /Editors: Representatives from Bristol-Myers Squibb Company will be available to answer questions from 3 to 5 p.m. today, July 19, at the Holiday Inn Crowne Plaza, 301-230-6715./
 /CONTACT: Patrick D. Donohue, 609-252-5685, or Robert F. Laverty, 609-252-5551, both of Bristol-Myers Squibb, or Chilton G. Goebel Jr. of Harris, Baio & McCullough, 215-440-9800, for Bristol-Myers Squibb/
 (BMY)


CO: Bristol-Myers Squibb Company; U.S. Food and Drug Administration ST: New Jersey, District of Columbia IN: MTC SU:

MK-JM -- PH019 -- 3178 07/19/93 15:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:326
Previous Article:COTT CORPORATION ANNOUNCES TWO-FOR-ONE SUBDIVISION OF SHARES APPROVED
Next Article:BOEING 767 FREIGHTER REACHES DESIGN MILESTONE
Topics:


Related Articles
BRISTOL-MYERS SQUIBB SUBMITS NEW DRUG APPLICATION TO FOOD AND DRUG ADMINISTRATION
BRISTOL-MYERS SQUIBB FILES NDA WITH FDA TO MARKET TAXOL
BRISTOL-MYERS SQUIBB'S VIDEX APPROVED BY FDA FOR BROADER USE
SMITHKLINE BEECHAM'S PAXIL GETS ADVISORY COMMITTEE OK; EXPERT PANEL RECOMMENDS MARKETING APPROVAL FOR NEW ANTIDEPRESSANT
BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON TAXOL
FDA PANEL RECOMMENDS CAPOTEN(R) FOR POST-HEART ATTACK PATIENTS
BRISTOL-MYERS SQUIBB FILES NEW DRUG APPLICATION FOR ANTI-AIDS DRUG ZERIT (STAVUDINE, d4T)
FDA CLEARS TAXOL(R) (PACLITAXEL) FOR USE IN TREATMENT OF METASTATIC BREAST CANCER AFTER FIRST-LINE THERAPY FAILS
BRISTOL-MYERS SQUIBB SUBMITS A SUPPLEMENTAL NEW DRUG APPLICATION FOR ZERIT(TM)
ZERIT(R) RECEIVES FULL MARKETING CLEARANCE UNDER FDA ACCELERATED APPROVAL REGULATIONS; CLINICAL BENEFIT PROVEN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters